Healthcare / BiotechnologyNasdaqGS
$3.21
-0.09 (-2.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-256.6M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$893M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-151.8%
↓Gross Margin
N/A
•Debt/Equity
0.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-244.2M · FCF $-144.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-244.2M | $-244.2M | $-266.8M | $-283.3M | $-269.5M | $-355.9M | $-285.3M | $-130.8M |
| EBITDA | $-193.0M | $-193.0M | $-255.3M | $-268.6M | $-256.9M | — | — | — |
| EPS | — | — | -1.16 | -1.46 | -1.43 | -2.14 | -21.92 | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.49 | 0.49 | 0.38 | 0.36 | 0.22 | — | — | — |
| Current Ratio | 1.29 | 1.29 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-144.8M | $-144.8M | $-256.6M | $-273.6M | $-310.9M | $-280.9M | $-161.9M | $-111.6M |
| Returns | ||||||||
| ROE | -151.8% | -151.8% | -106.5% | -98.5% | -54.0% | -48.9% | 67.7% | 91.7% |
| Valuation | ||||||||
| P/B | 5.32 | 5.32 | 1.58 | 3.45 | 1.37 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | — | — | 20.5% | -2.1% | — | 90.2% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+47.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.16 → n/d
Residual
+47.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.